HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2006.07.030v1 j.jacc.2006.07.030v2 48/6/1277    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McNamara, D. M. Articles by Worcel, M. Search for Related Content PubMed PubMed Citation Articles by McNamara, D. M. Articles by Worcel, M.

EXPEDITED REVIEW

Aldosterone Synthase Promoter Polymorphism Predicts Outcome in African Americans With Heart Failure

Results From the A-HeFT Trial

Dennis M. McNamara, MD^_*,_*, S. William Tam, PhD, Michael L. Sabolinski, MD, Page Tobelmann, BS^_*, Karen Janosko, MSN^_*, Anne L. Taylor, MD, Jay N. Cohn, MD, Arthur M. Feldman, MD, PhD and Manuel Worcel, MD

^_* From the University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
NitroMed Inc., Lexington, Massachusetts
University of Minnesota, Rochester, Minnesota
Thomas Jefferson Medical College, Philadelphia, Pennsylvania

Manuscript received February 7, 2006; revised manuscript received June 12, 2006, accepted July 10, 2006.

^_* Reprint requests and correspondence: Dr. Dennis M. McNamara, Heart Failure/Transplantation Program, University of Pittsburgh Medical Center, 566 Scaife Hall, 200 Lothrop Street, Pittsburgh, Pennsylvania 15241 (Email: mcnamaradm{at}upmc.edu).

OBJECTIVES: We sought to evaluate the effect of the aldosterone synthase promoter polymorphism on heart failure outcomes for subjects in the African American Heart Failure Trial (A-HeFT).

BACKGROUND: Genetic heterogeneity modulates clinical outcomes in subjects with heart failure (HF); however, little data exist in African American populations. A common polymorphism exists in the promoter region of the aldosterone synthase gene (CYP11B2) at position –344 (T/C). The –344C allele, associated with higher aldosterone synthase activity, has been linked to hypertension; however, its impact on outcomes in HF is unknown.

METHODS: A total of 354 subjects from A-HeFT participated in the GRAHF (Genetic Risk Assessment of Heart Failure in African Americans) substudy and were genotyped for the aldosterone synthase polymorphism. Patients were followed prospectively, and event-free survival (freedom from death and HF hospitalization) compared by CYP11B2 genotype.

RESULTS: Of the cohort, 218 patients were TT, 114 CT, and 22 patients were CC. Baseline etiology, blood pressure, and functional class were not significantly different among the 3 cohorts. The C allele was associated with significantly poorer HF hospitalization-free survival with the best survival among TT subjects, intermediate for heterozygotes, and the poorest for CC homozygotes (p = 0.018), and a higher rate of death (% death TT/TC/CC = 1.8/3.5/18.2, p = 0.001). The TT genotype, more prevalent in blacks, was associated with greater impact of fixed combination of isosorbide dinitrate and hydralazine on the primary composite end point (p = 0.01).

CONCLUSIONS: The aldosterone synthase promoter –344C allele linked to higher aldosterone levels is associated with poorer event-free survival in blacks with HF. The role of aldosterone receptor antagonists in diminishing this apparent genetic risk remains to be explored.

Abbreviations and Acronyms   A-HeFT = African-American Heart Failure Trial   CYP11B2 = aldosterone synthase gene locus   GRACE = Genetic Risk Assessment of Cardiac Events trial   GRAHF = Genetic Risk Assessment of Heart Failure in African Americans substudy   I/H = isosorbide dinitrate and hydralazine   LVDD = left ventricular end-diastolic diameter   LVEF = left ventricular ejection fraction   MLHFQ = Minnesota Living with Heart Failure Questionnaire   NO = nitric oxide   QoL = quality of life   SF-1 = steroidogenic transcription factor-1

This article has been cited by other articles:

				K. C. Ferdinand Fixed-dose isosorbide dinitrate-hydralazine: race-based cardiovascular medicine benefit or mirage? J. Law Med. Ethics, September 1, 2008; 36(3): 458 - 463. [PDF]

				C. W. Yancy, W. T. Abraham, N. M. Albert, R. Clare, W. G. Stough, M. Gheorghiade, B. H. Greenberg, C. M. O'Connor, L. She, J. L. Sun, et al. Quality of Care of and Outcomes for African Americans Hospitalized With Heart Failure: Findings From the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) Registry J. Am. Coll. Cardiol., April 29, 2008; 51(17): 1675 - 1684. [Abstract] [Full Text] [PDF]

				W.H. W. Tang and G. S. Francis The Year in Heart Failure J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2575 - 2583. [Full Text] [PDF]